Ultra-widefield fundus imaging is powerful. It allows us to see a much wider area of the retina in a single image — often without pupil dilation. That is why it is widely used for screening diabetic retinopathy, retinal detachment, and retinal vascular diseases.

But there is an important limitation.

Ultra-widefield images are not the same as conventional color fundus photographs. Especially in SLO-based ultra-widefield pseudocolor images, the color tone, contrast, and lesion appearance can differ from what clinicians are used to seeing in standard fundus photos. And while UWF imaging is excellent for the peripheral retina, detailed interpretation of central structures such as the macula and optic disc can sometimes be limited by image characteristics, artifacts, and structural representation.

That matters. Because the macula and optic disc are critical for diagnosing major vision-threatening diseases such as age-related macular degeneration, glaucoma, diabetic retinopathy, and retinal vein occlusion.

This is why we developed UWF-FOCUS.

UWF-FOCUS is not just an image-sharpening tool. It automatically identifies the macular and optic disc regions in ultra-widefield fundus images and enhances contrast, boundaries, and fine structural visibility in those clinically important areas. The goal is simple: to preserve the strength of ultra-widefield imaging — its broad field of view — while improving the assessment of central retinal structures.

In our ARVO 2026 presentation, we showed that UWF-FOCUS has the potential to expand ultra-widefield imaging beyond peripheral retinal screening, toward broader evaluation of central retinal diseases.

For us, this is an important direction. We are focused on building deeper ophthalmology AI — technology that helps interpret retinal images closer to the way eye specialists actually think and diagnose. That is the direction of CrystarVision. Not just detecting signals. Not just making images look better. But building AI that supports clinical diagnosis in ophthalmology. #CrystarVision #Reticare #UWF #FundusImaging #OphthalmologyAI #MedicalAI #ARVO2026 #Glaucoma #AMD #DiabeticRetinopathy #RetinalVeinOcclusion